|
gptkbp:instance_of
|
gptkb:Clinical_Trials
|
|
gptkbp:aims_to_improve
|
efficacy of combination therapy
|
|
gptkbp:concluded_on
|
gptkb:true
|
|
gptkbp:conducted
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:contributes_to
|
FDA approvals
|
|
gptkbp:evaluates
|
safety profile
|
|
gptkbp:focuses_on
|
gptkb:cancer_treatment
|
|
gptkbp:has_collaborations_with
|
academic institutions
research organizations
|
|
gptkbp:has_endpoints
|
response rate
overall survival
progression-free survival
|
|
gptkbp:has_ethical_approval
|
gptkb:true
|
|
gptkbp:has_impact_on
|
clinical practice
treatment guidelines
|
|
gptkbp:has_informed_consent
|
gptkb:true
|
|
gptkbp:has_location
|
multiple countries
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Check Mate trials
|
|
gptkbp:includes
|
gptkb:Nivolumab
Ipilimumab
|
|
gptkbp:innovation
|
gptkb:true
|
|
gptkbp:investigates
|
immune checkpoint inhibitors
|
|
gptkbp:involves
|
multiple cancer types
|
|
gptkbp:is_collaborative_with
|
multinational
|
|
gptkbp:is_compared_to
|
monotherapy vs combination therapy
|
|
gptkbp:is_funded_by
|
pharmaceutical companies
|
|
gptkbp:is_monitored_by
|
regulatory agencies
|
|
gptkbp:is_part_of
|
Oncology research
|
|
gptkbp:is_related_to
|
gptkb:immunotherapy
pharmaceutical development
cancer immunology
|
|
gptkbp:is_reported_at
|
medical conferences
|
|
gptkbp:is_significant_for
|
patient outcomes
cancer research
therapeutic advancements
|
|
gptkbp:is_tested_for
|
Phase 1
Phase 2
Phase 3
|
|
gptkbp:popularized_by
|
gptkb:true
|
|
gptkbp:provides_information_on
|
adverse events
clinical outcomes
quality of life assessments
long-term survival rates
|
|
gptkbp:published_by
|
peer-reviewed journals
|
|
gptkbp:recruitment
|
patients with lung cancer
patients with melanoma
patients with head and neck cancer
patients with renal cell carcinoma
|
|
gptkbp:result
|
medical journals
|
|
gptkbp:started_in
|
gptkb:2012
|
|
gptkbp:uses
|
biomarkers
|
|
gptkbp:bfsParent
|
gptkb:Opdivo
|
|
gptkbp:bfsLayer
|
5
|